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Abstract 
The novel human gene family encoding Neuronal Leucine Rich Repeat (NLRR) proteins 
were identified as prognostic markers from our previous screening of primary 
neuroblastoma (NB) cDNA libraries. Of the NLRR gene family members, NLRR1 and 
NLRR3 are associated with the regulation of cellular proliferation and differentiation, 
respectively. However, the functional regulation and clinical significance of NLRR2 in 
NB remain unclear . We evaluated the expression of NLRR2 in 78 NBs by quantitative 
real time PCR. High levels of NLRR2 expression were significantly associated with a 
poor prognosis of NB (p=0.0009). In vitro experiments showed that the exogenous 
expression of NLRR2 enhanced cellular proliferation and induced resistance to retinoic 
acid (RA)-mediated cell growth inhibition in NB cells. Knock-down of NLRR2 exhibited 
growth inhibition effects in NB cells and enhanced RA-induced cell differentiation. In 
NB cells treated with RA, NLRR2 expression was increased and was correlated with the 
upregulation of c-Jun, a member of the activator protein-1 (AP-1) family. The 
expressions of NLRR2 and c-Jun were suppressed by treatment with a JNK inhibitor, 
which ameliorated the promoter activity of the NLRR2 gene. An AP-1 binding consensus 
was identified in the NLRR2 promoter region to which c-Jun was recruited. Moreover, 
knock-down of c-Jun reduced NLRR2 expression, suggesting that NLRR2 is an inducible 
gene regulated by the JNK pathway to enhance cell survival and inhibit NB cell 
differentiation. Therefore, NLRR2 might have an important role in NB aggressiveness 
and might be a potential therapeutic target for the treatment of RA resistant and 
aggressive NBs as well as other cancers. 
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Introduction 
Neuroblastoma (NB) is the most common form of malignancy in early childhood and is 
derived from the sympathoadrenal lineage of neural crest progenitor cells.1 NB exerts 
heterogeneous clinical behavior. Some NBs regress spontaneously while others progress 
to highly metastatic tumors with a poor prognosis despite intensive multimodal therapy.2 
However, the pathogenesis of NB is poorly understood as very few gene defects have 
been identified in this often-lethal tumor. Frequently detected genetic alterations are 
limited to MYCN amplification and ALK activation.3-5 Aberrant gene expression patterns 
have been shown to be important in the clinical outcome of NB. For example, high 
expression of the neurotrophic receptor TrkA has been identified as a prognostic factor 
for a favorable outcome because it inhibits tumor growth and angiogenesis, whereas 
TrkB and its ligand, brain-derived neurotrophic factor, are associated with aggressive NB 
with MYCN amplification that enhances tumor growth and angiogenesis.4,6-8 Some 
factors related to NB pathogenesis are involved in proliferation, differentiation, and 
metastasis. However, little is known about their biological function with regards to tumor 
growth aggressiveness and this has negatively impacted on the development of 
therapeutic drugs. Therefore, studies on the molecular mechanisms of NB are required to 
develop new therapeutic strategies to treat aggressive NB. 
Retinoic acid is an important metabolite that functions as a morphogen in the developing 
nervous system in vivo, and which induces the differentiation of neuronal cells in vitro.9 
It has been implicated in human NB because RA treatment inhibits NB proliferation, 
differentiates into neuronal-like cells, reduces cell migration and invasiveness.10-13 These 
properties have been used as a basis for the clinical application of RA, one of the limited 
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drugs  currently used to treat cancers.10-14 It has become standard practice to treat high-
risk NB patients after marrow or stem cell transplantation.15 Despite multiple clinical 
efforts, the prognosis remains poor for this enigmatic disease because of the high rate of 
resistance and metastasis in acute promyelocytic leukemia as well as human NB cell lines 
that express multidrug resistance genes during differentiation by RA.16,17 Therefore, to 
overcome drug resistance in  the aggressive NBs, it is important to identify factors that 
contribute to RA resistant and RA-mediated NB cell differentiation provides a good 
model for this study. RA binds to RAR and activates a signal transduction pathway that 
involves multiple cytoplasmic signaling molecules such as JNK and ERK. The JNK 
pathway has been proposed to induce a signaling cascade during RA-mediated 
differentiation of NB as well as non–NB.18-20 The downstream component of JNK/SAP 
MAPK is AP-1, which is a homo- or heterodimeric complex consisting of c-Jun, c-fos, 
Maf and ATF2. Based on the cellular context, the composition of the AP-1 dimeric 
complexe determines its  functions in the regulation of differentiation, proliferation, and 
apoptosis.19-23 However, the direct molecular mediator in transmitting RA-signal to 
regulate neuritis extension in NB has remained unknown. Here, we report that NLRR2 
acts as an inhibitor for the RA-mediated differentiation of NB, therefore contribute to NB 
aggressiveness.  
NLRR2 is a member of the NLRR genes family that encode a glycosylated 
transmembrane protein with a leucine rich repeat (LRR) domain containing 11 or 12 LRR, 
an immunoglobulin c2-type domain, and a type III fibronectin domain in its extracellular 
domain. Like other NLRR family proteins, NLRR2 has highly conserved amino acid 
sequence in the extracellular domain which has substrate or chemical binding sites and 
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four potential glycosylation sites. NLRR2 also possesses ww interacting domains in the 
short intracellular region, which mediate protein-protein interactions and might provide a 
basis of signaling events for NLRR function in tumorigenesis.24-26 We previously reported 
that NLRR1 enhances epidermal growth factor (EGF)-mediated MYCN induction in NB 
resulting in the acceleration of tumor growth in vivo and that a high expression of 
NLRR1 mRNA levels is associated with a poor prognosis of NB. In contrast, low NLRR3 
expression levels were correlated with a poor prognosis in NB patients.27-29 However, 
very little is known about the role of NLRR2 in tumor progression except it has been 
reported to be amplified and overexpressed in malignant gliomas.30 The current study 
reveals that RA functions as a negative feedback regulator through the upregulation of 
NLRR2 during RA-mediated differentiation in NBs. NLRR2 might be a useful 
pharmacological indicator to predict RA efficiency in NB treatment. 
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Results 
Expression of NLRR2 is associated with the poor prognosis of neuroblastoma and 
enhances oncogenic transformation in vitro and in vivo.  
Previously, we identified NLRR family genes which are differentially expressed between 
favorable and unfavorable NBs from the screening of nearly 2000 novel genes using our 
unique NB cDNA libraries. Human NLRR2 is a highly expressed gene in NB-derived cell 
lines26  and may be used to define clinical relevance between favorable and unfavorable 
NBs. We performed gene expression analysis by real-time PCR using NB cDNA from 78 
patients. Kaplan-Meier survival curves indicated that NBs with high NLRR2 expression 
significantly associated with a poor clinical prognosis (P<0.001) (Figure 1a). To 
investigate the oncogenic effect of NLRR2 in NBs, we stably expressed NLRR2 in SK-N-
BE cells that resulted in significant increas of proliferation (P<0.001) compared with the 
mock stable cells (Figure 1b). However, these findings by real-time PCR data do not 
demonstrate why NLRR2 is a poor prognosis factor for NB patients. Therefore, we 
investigated the biological function of NLRR2 by overexpressing or knocking down 
NLRR2 and measuring cell growth. Overexpression of NLRR2 resulted in a significant 
(P<0.01) increase in NB cell proliferation (Figures 1c and d). In addition, the down 
regulation of NLRR2 by siRNA-mediated knock-down significantly (P<0.01) reduced 
SK-N-BE cell growth (Figure 1e). To confirm the function of NLRR2 in vivo, we locally 
treated mice bearing tumors derived from SK-N-BE cells with atelocollagen complexed 
with siNLRR2 . Compared with the control siRNA group, siNLRR2 treatment 
significantly reduced the tumor growth of SK-N-BE xenograft tumors (Figures 1f, g and 
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h). These data suggest that the function of NLRR2 is involved in tumorigenesis and is 
associated with a poor prognosis of NB. 
NLRR2 inhibits differentiation in NB cells 
To confirm whether NLRR2 has a function in cell growth and differentiation processes of 
NB, we investigated morphological changes in cells upon the modulation of NLRR2 
expression. After transfection of siNLRR2, the growth of SK-N-BE cells was 
significantly repressed by RA treatment (Figures 2a and b). Interestingly, the 
differentiation data revealed that NLRR2-knockdown cells were more susceptible to RA-
mediated differentiation (Figures 2c and d). The enhanced cell differentiation by NLRR2 
knock-down was confirmed by a higher level of GAP43, a neuronal differentiation 
marker expression (Figure 2e). GAP43 is also associated with neuritis extension.31-33 
These data suggest that NLRR2 knock-down retards cell growth and enhances cell 
differentiation induced by RA treatment.  
 
c-Jun is important for the regulation of NLRR2 expression 
We next examined NLRR2 expression during RA-induced differentiation 
(Supplementary figure S2) of NB cells. Interestingly, mRNA and protein levels of 
NLRR2 expression were elevated in RA-treated NB cells (Figures 3a and b). Consistent 
with previous reports showing the RA-mediated induction of c-Jun18,19,34 c-Jun 
expression in NB cells was also increased upon RA treatment. To investigate whether c-
Jun was important for the regulation of NLRR2 expression, NB cells were transiently 
transfected with c-Jun siRNA, resulting in reduced expressions of NLRR2 mRNA and 
protein (Figures 3c and d). Because RA treatment failed to rescue the NLRR2 expression 
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in c-Jun knock-down cells, these data demonstrated that c-Jun functions by regulating 
RA-induced NLRR2 expression.  
 
RA enhances the recruitment of c-Jun to the NLRR2 promoter 
To clarify the transcriptional regulation of the NLRR2 gene, we generated luciferase 
reporter constructs containing −790 bp to +110 bp fragments of the NLRR2 gene where 
+1 represents the transcriptional initiation site. The promoter activity determined by 
luciferase reporter analysis was increased in response to RA treatment (Figure 4a). The 
study using a series of deletion mutants of the promoter constructs showed that the 
luciferase activity was highest in between the −790 and −560 region, which contains a c-
Jun binding site of TPA-responsive element (TRE), TGACAAA. We performed a 
promoter assay in HeLa cells because they have a high transfection efficiency. RA-
treatment induced NLRR2 and c-Jun expression (Supplemental figure S3). We also 
confirmed similar luciferase activity data in SK-N-BE cells (Figure 4b) using a −790 to 
+110 promoter construct including AP-1 binding site. Next, we performed a chromatin 
immunoprecipitation (ChIP) assay to determine whether c-Jun directly binds to the 
promoter region of NLRR2. As shown in Figure 4c, the recruitment of c-Jun to the 
NLRR2 promoter was increased by RA treatment, indicating that NLRR2 is 
transcriptionally regulated by c-Jun.     
 
NLRR2 expression is regulated by the JNK pathway  
NLRR2 promoter activity was suppressed in SK-N-BE cells following treatment with a 
JNK inhibitor (Figure 5a). To confirm that NLRR2 is regulated through the JNK pathway, 
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we treated TGW and SK-N-BE cells with a JNK inhibitor to examine the expression of 
NLRR2. As expected, JNK inhibition reduced the expression of NLRR2 and c-Jun in 
both the mRNA and protein levels (Figures 5b and c, respectively). Furthermore, the RA-
mediated increased expression of NLRR2 was reduced by JNK inhibition (Supplemental 
figure S4). To confirm the function of the JNK pathway in the regulation of NLRR2 
expression, we used sorbitol, which induces JNK activation.35,36 The phosphorylation of 
JNK and c-Jun as well as the expression of NLRR2 were induced by sorbitol treatment in 
SK-N-BE cells and co-treatment with a JNK inhibitor ameliorated the induction of 
NLRR2 expression (Figures 5d and e). Thus, the JNK pathway is particularly important 
for regulating NLRR2 expression in NB cells. 
 
NLRR2 exhibits survival to RA and other stress-mediating agents in NB cells.  
Because the JNK pathway was induced by RA and sorbitol was involved in the regulation 
of NLRR2 expression, we next treated NB cells with other agents that cause cellular 
stress. Treatment with tunicamycin (TM), an endoplasmic reticulum stress agent and 
cisplatin (CDDP), a DNA-damaging agent, induced NLRR2 expression in NB cells 
(Figures 6a and b). To examine whether the induced NLRR2 was associated with cell 
survival against cellular stress, NLRR2-stably expressing cells were treated with RA and 
TM and cell viability was examined. As shown in Figure 6c and 6d, NLRR2-stable cells 
were significantly resistant to RA and TM treatment compared with control cells. We 
also checked the morphology of the NLRR2 stable and mock cells upon RA-treatment to 
study the differentiation function of NLRR2. Data showed that the stable expression of 
NLRR2 significantly (P<0.01) inhibited RA-induced differentiation compared with 
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controls (Supplemental figure S5). Therefore, after the induction of NLRR2 by cellular 
stress-mediating agents, NLRR2 in turn reduce their cytotoxicity of NB cells.  
 
Discussion 
Our results clearly demonstrate the clinical relevance of NLRR2 expression and its 
function in RA-induced cell differentiation. NLRR2 enhances the cell survival of RA-
treated NB cells, while other family members, NLRR1 and NLRR3, are associated with 
cell proliferation and differentiation.28,29 In addition, mouse NLRR3 was reported to 
modulate MAPK signaling through the EGFR pathway,35 indicating that NLRR family 
proteins might have functional relevance in cell signaling events. The present study 
suggests that the high expression of NLRR2 is significantly associated with the poor 
prognosis of NB, consistent with data analyzed using an R2 platform. Of note, a similar 
observation was reported for malignant gliomas,30 Local treatment of siNLRR2 in a 
mouse xenograft model of NB significantly reduced tumor growth, suggesting that the 
low expression of NLRR2 solely restricts tumor progression and serves as a prognostic 
marker of NB. Further study may clarify the clinical significance of NLRR2 expression 
in tumorigenesis. 
Our in vitro experiments that modulated the expression of NLRR2 in NB cells indicated 
the potential molecular mechanisms of how NLRR2 might be involved in the poor clinical 
outcome of NB. NLRR2-overexpressing cells showed enhanced cell proliferation and a 
significant resistance phenotype to RA treatment. In contrast, NLRR2 knock down cells 
were more susceptible to RA-mediated cell growth inhibition and exhibited significantly 
(P<0.01) increased numbers of differentiated cells compared with control cells. These 
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data suggest that the function of NLRR2 is to inhibit the differentiation process and 
support the cell survival of RA-treated cells.  
RA is a potent differentiation inducer of NB cells and causes a marked suppression of 
MYCN expression.29,36,37 However, our previous observation revealed that NLRR2 
expression was not correlated with MYCN expression (data not shown). In the present 
study, we found that c-Jun plays a key role in regulating NLRR2 gene expression in RA-
treated NB cells. RA-treated NB cells exhibited the co-induction of NLRR2 and c-Jun, 
whereas expressions of other AP-1 members such as c-fos and ATF-2 were reduced 
(Supplemental figure S6). The activity of JNK appears to be important for the induction 
of NLRR2, which is consistent with previous reports regarding the induction and 
activation of c-Jun in a downstream of the JNK pathway after RA treatment.19,20 It is 
noteworthy that other stress-inducing agents such as TM and CDDP also induced NLRR2 
in NB cells. The significant survival difference observed in the clinical subsets with low 
and high expressions of NLRR2 may be explained by the stress-induced up-regulation of 
NLRR2, which in turn contributes to the drug resistance of NB cells. An anti-apoptotic 
role of activated c-Jun/AP-1 transcription factor was reported to protect human tumor 
cells from DNA-damaging agents including TM and CDDP (38). Thus, the effects 
observed in this study suggest that activated AP-1 complexes exert a favorable influence 
on cell survival that counters diverse external stresses induced by drugs. 
Although the JNK and p38MAPK pathways can potentially synergize to induce AP-1 
transcriptional activity and share c-Jun as a common substrate (39), we found a limited 
effect of p38MAPK inhibition on RA-induced differentiation as well as NLRR2 
expression in NB cells (data not shown). There is considerable evidence that neurite 
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outgrowth stimulated by RA is partially dependent on JNK activity (18). c-Jun/AP-1 was 
reported to be involved in neuronal differentiation and protection from apoptosis in NB 
cells.40 However, the relevant functions and target genes of AP-1 in neuronal 
differentiation have not been elucidated yet. In particular, it is unclear whether AP-1 in 
NB cells facilitates cell death or, conversely, is a part of a protective response against 
differentiation or apoptosis. Our experimental evidence suggests that c-Jun/AP-1 in RA-
treated NB cells plays a protective role by up-regulating the expression of NLRR2. 
Future studies might explain why the prognosis of NB treated with RA remains poor, 
with a high rate of resistance and metastasis.16,17  
The present study indicates the clinical relevance of NLRR2 and a regulatory mechanism 
of NLRR2 transcription in RA-treated NB cells. The expression of NLRR2 is 
transcriptionally regulated by the JNK-c-Jun axis and enhances cell survival in drug-
treated NB cells. Therefore, NLRR2 might be a key target molecule for the development 
of new therapeutic strategies to overcome RA resistance in aggressive NLRR2-
expressing NBs. 
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Materials and Methods 
Cell culture 
Human NB-derived TGW, SMS-SAN and non-NB HeLa cells were collected from The 
Children’s Hospital of Philadelphia cell line bank (Philadelphia, PA, USA). SK-N-BE 
and NB cells were collected from the European Collection of Cell Cultures (Wiltshire, 
UK) cell bank. NB cells were maintained in RPMI 1640 medium (Wako, Osaka, Japan), 
supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen, CA, USA), 50 
μg/ml penicillin, and 50 μg/ml streptomycin (Invitrogen). HeLa cells were maintained in 
DMEM medium (Wako) with the same supplements. All cells were cultured in a 
humidified chamber provided with 5% CO2 at 37°C.  
 
siRNA-mediated knock-down 
A mixture of two sets of siRNA sense and antisense sequences was used: siNLRR2-1: 5′-
CUACAGGAACUCUAUCUCATT-3′ (sense); 5′-UGAGAUAGAGUUCCUGUAGTT-
3′ (antisense); siNLRR2-2: 5′-CCAACUUGGAGAUACUCAUTT-3′ (sense); 5′-
AUGAGUAUCUCCAAGUUGGTT-3′ (antisense), which were designed to target human 
NLRR2 (Takara, Shiga, Japan). c-Jun siRNA was purchased from Cell Signaling 
Technology (Boston, MA, USA). Control non-targeting siRNA was purchased from 
Thermo Fisher Scientific (Waltham, MA, USA). NB cells were transfected with siRNA 
by forward-transfection according to the manufacturer’s protocol using Lipofectamine 
RNAiMAX reagent (Invitrogen). We used siRNA (concentration 50 nM) for siNLRR2 
and 200 nM for si-c-Jun because these concentrations were determined to work well in a 
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preliminary study (Supplemental figure S1). Forty-eight hours after incubation at 37°C in 
a CO2 incubator, gene knock-down was evaluated by quantitative real-time RT-PCR. 
 
Cell growth assays 
SK-N-BE and SMS-SAN cells were transfected with an NLRR2 expression vector using 
Lipofectamine 2000 in Opti-MEM medium, which was replaced after 12 hours of 
transfection with RPMI medium supplemented with heat-inactivated 10% FBS for 24 
hours. Cells were then plated into 96-well plates at a cell density of 500 cells/well and 
their proliferation was monitored by a live cell imaging system (IncuCyte, Essen 
Bioscience, Morgan Rd, MI,USA).  
 
RT-PCR and quantitative real-time PCR (qPCR) 
RT-PCR was performed to check the expression of NLRR2, c-Jun, GAP43 and GAPDH. 
To perform RT-PCR, total RNA was extracted from cells by RNeasy Mini Kit (Qiagen, 
Valencia, CA, USA) according to the manufacturer’s protocol and reverse transcription 
was performed with SuperScript II reverse transcriptase (Invitrogen). The specific 
primers used were as follows: NLRR2, 5′-cccgagactgtgattccat-3′ and 5′-
aagttgctgaggccagaaaa-3′; c-Jun, 5′-agcggaccttatggctacag-3′ and 5′-ccgttgctggactggattat-
3′; GAP43, 5′-gagagcagttcgacctagtcc-3′ and 5′-tgcggccttaatgagctttat-3′; and GAPDH, 5′-
acctgacctgccgtctagaa-3′ and 5′-tccaccaccctgttgctgta-3′. cDNAs prepared from primary 
NB tissue samples and cultured cells were used to quantify β-actin using a β-actin control 
reagent kit purchased from Applied Biosystem (Drive Foster City, CA, USA). NLRR2 
and c-Jun mRNA expressions were measured by the SYBR green real-time system using 
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the following primers: NLRR2, 5′-ctcctgagggccattgaca-3′ and 5′-cgccaatcatgagtatctccaa-
3′; and c-Jun, 5′-cggagaggaagcgcatga-3′ and 5′-ttcctttttcggcacttgga-3′. All these real-time 
quantifications were performed using a 7500 Real Time PCR System (Applied 
Biosystems).  
 
Immunoblotting 
Whole cell lysates were prepared using ice-cold RIPA buffer containing proteinase and 
phosphatase inhibitors. Protein concentration was measured using a BCA protein assay 
kit (Thermo Scientific, Rockford, IL, USA) according to the manufacturer’s instructions. 
Equal amounts of proteins were separated by SDS-PAGE and electrophoretically 
transferred to nitrocellulose membranes. Membranes were then blocked with 5% skim 
milk at room temperature for 1 hour. After blocking, the membranes were incubated at 
4°C overnight with anti-NLRR2 (MBL, Nagoya, Japan), anti-c-Jun, anti-JNK, anti-
phospho-JNK, anti-phospho-cJun, anti-GAP43 (Cell Signaling Technology) and anti-β-
actin (Sigma-Aldrich, St. Louis, MO, USA) antibodies.  
 
RA treatment 
To study the effect of RA (Sigma-Aldrich) on NLRR2 expression, TGW cells (1 µM) and 
SK-N-BE, SMS-SAN and HeLa cells (2.5 µM) were treated with RA or dimethyl 
sulfoxide. After the indicated time period, NLRR2 expression was measured by RT-PCR, 
qPCR and western blot analysis. To investigate the effect of RA on NB cell growth and 
differentiation, NLRR2 was stably expressed or knocked down using an NLRR2 
expression vector or siNLRR2, respectively. After 36 hours of transfection, the cells were 
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seeded at 5 × 103 (stably expressing cells) or 1 × 103 (knock-down cells) in 96-well 
culture plates (Becton Dickinson, Franklin Lakes, NJ, USA) and allowed to adhere 
overnight followed by RA treatment. At the indicated time points, cell survival was 
determined using IncuCyte (Essen Bioscience). 
 
Luciferase assay 
An NLRR2 promoter region (−790 to +110) was generated by PCR amplification using 
human placental genomic DNA and cloned into a pGL3 basic vector (Promega, 
Fitchburg,WI, USA). Cells were plated in a 96-well plate at a density of 2 × 103/well and 
transiently transfected with the indicated luciferase reporter constructs (200 ng). At 48 
hours after transfection, cell lysates were prepared using passive lysis buffer (PLB) and 
their luciferase activity was measured by dual luciferase assay kit according to the 
manufacturer’s protocol (Promega). Renilla luciferase was used as an internal control.  
 
ChIP assay 
A ChIP assay was performed using a ChIP assay kit according to the protocol provided 
by Millipore (Billercia, MA, USA). Precipitated DNA and control input DNA were 
purified using a QIAquick PCR purification kit (Qiagen). Purified DNA was amplified by 
PCR using the following set of primers: 5′-gttcctgactgaaattgacc-3′ and 5′-
ttgcaaaggccaggagacgaatg-3′ targeting the NLRR2 core promoter region (−790 to +110). A 
5′-tcaaggagcgcctggctct-3′ and 5′-atggcagaatcccaatccg-3′ primer set was used for the 
region that does not contain any AP-1 consensus sequence. 
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In vivo tumorigenicity assays 
SK-N-BE cells at a density of 1 × 107 were subcutaneously inoculated into 7-week-old 
female SCID mice. One week after inoculation, when the tumors had an average volume 
of 70 ± 30 mm3, a mixture of 1 nmol of control or a mixture of two sets of NLRR2 siRNA 
and 200 µl of atelocollagen (Koken, Tokyo, Japan) was injected to the site of the tumor 
to evaluate the growth inhibition effect. Injections were administered twice at 7-day 
intervals. Tumor size was measured every week after they were visible. The volume of 
each tumor was calculated using the formula: Tumor volume=(length × width2)/2. 
Animal experiments were performed in compliance with the regulations for animal 
experiments of IACUC. 
Statistical analysis 
Results were shown as the mean ± standard deviation (SD). The Student’s t-test was used 
to compare the differences of means between two groups. P < 0.05 was considered 
statistically significant. 
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Figure legends 
Figure 1. NLRR2 is correlated with poor survival outcome in human NB and regulates 
tumor cell growth in vitro and in vivo. (a) Kaplan-Meier survival curves. Expression 
levels of NLRR2 were designated as high (n=23, red line) and low (n=55, blue line). High 
NLRR2 mRNA expression was significantly correlated with poor survival outcome 
(p=0.001). (b) Mock and NLRR2 bulk stable cells were generated in SK-N-BE cells and 
NLRR2 expressions were confirmed by western blotting (left panel). Stable expression of 
NLRR2 exhibited significant (p=0.001) enhancement of cell growth (right panel). (c, d) 
NLRR2 was transiently overexpressed in SK-N-BE and SMS-SAN cells and confirmed 
by western blotting. Over-expression of NLRR2 significantly (p<0.05) enhanced cell 
growth in SK-N-BE (c) and SMS-SAN (d) cells. (e) In vitro knock-down of NLRR2 
reduced NB cell growth. (f) SCID mice were subcutaneously inoculated with 1 × 107 SK-
N-BE cells. Two weeks after inoculation, when the tumors had an average volume of 70 
± 30 mm3, 1 nmol of control siRNA or a mixture of two siNLRR2 siRNA with 200 µl of 
atelocollagen (Koken, Tokyo, Japan) was injected to the tumor mass to evaluate the 
growth inhibition effect. siNLRR2 treatment significantly (p<0.01) reduced the tumor 
growth compared with the control siRNA-treated group. (g, h). Four weeks after 
treatment, the tumors were removed (g). The tumor weight was significantly (p<0.01) 
reduced in the siNLRR2-treated group compared with the control siRNA group (h).    
 
Figure 2. NLRR2 knock down cells are susceptible to RA-mediated inhibition of cell 
survival and differentiation. (a, b) SK-N-BE cells were transiently transfected with 
control siRNA or siNLRR2 and cell growth was measured using a real-time cell imaging 
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system. Knock-down of NLRR2 expression was confirmed by quantitative real time PCR 
(a). The inhibition of cell growth by RA treatment was significantly increased in NLRR2 
knock down cells (p<0.01). (c, d). SK-N-BE cells were transiently transfected with 
control siRNA or siNLRR2 followed by RA (2.5 μM) treatment for three days. The 
percentage of differentiated cells per field was counted (5 fields per well, 5 wells in each 
group). Data are presented as the mean ± SD. (e) SK-N-BE cells were transiently 
transfected with control siRNA or siNLRR2 followed by RA treatment for the indicated 
time period. GAP43, a marker for the neuronal differentiation, and NLRR2 expressions 
were examined by western blot analysis. NLRR2 knock down cells with RA treatment 
showed a higher expression of GAP43. 
Figure 3. c-Jun is important for regulating NLRR2 expression induced by RA. (a, b) 
NLRR2 and c-Jun were upregulated during RA-mediated differentiation at the mRNA (a) 
and protein (b) levels in SK-N-BE, TGW and SMS-SAN cells. NB cells were treated 
with RA (1.0 μM for TGW cells, 2.5 μM for SK-N-BE and SMS-SAN cells) for the 
indicated time periods. NLRR2 and c-Jun expressions were determined by RT-PCR and 
western blot analysis. (c, d). SK-N-BE cells were transfected with control or c-Jun siRNA. 
Forty-eight hours after transfection, the expressions of c-Jun and NLRR2 were measured 
by quantitative real time PCR (c). c-Jun knock-down cells treated with RA showed a 
reduced expression of NLRR2 (d). 
Figure 4. NLRR2 transcription is enhanced by RA through the recruitment of c-Jun onto 
the promoter of NLRR2 while JNK inhibition suppresses the promoter activity. (a) 
Luciferase reporter constructs −790, +110; −560, +110; −315, +110; −147, +110 and −47, 
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+110 (left panel) with renilla luciferase vector were introduced to HeLa cells and the 
promoter activity was measured by dual luciferase assay. RA treatment enhanced the 
NLRR2 promoter activity (−790, +110) (right panel). (b) RA treatment enhanced NLRR2 
promoter activity in SK-N-BE cells. SK-N-BE cells were transfected with NLRR2 core 
luciferase reporter constructs (−790, +110) with renilla luciferase vector followed by RA 
treatment for 36 hours and promoter activity was measured. (c) RA-mediated c-Jun 
recruitment to the NLRR2 promoter region containing AP-1 consensus sequence was 
confirmed by ChIP assays. 
Figure 5. The JNK pathway is important for regulating NLRR2 expression. (a) JNK 
inhibition reduced NLRR2 promoter activity in SK-N-BE cells. SK-N-BE cells were 
transfected with the (−790, +110) promoter construct and a Renilla luciferase vector. At 
24 hours after the transfection, cells were treated with SP600125 (50 μM) for 24 hours 
and luciferase assay was performed. (b, c) TGW and SK-N-BE cells were treated with 
SP600125 for 24 hours and the expression of c-Jun and NLRR2 were analyzed by 
western blotting and RT-PCR analyses. JNK inhibition by SP600125 suppressed the 
expression of NLRR2 and c-Jun at mRNA (b) and protein levels (c) in TGW and SK-N-
BE cells. (d, e) JNK activation by sorbitol treatment (300 μM) in SK-N-BE cells induced 
NLRR2 expression which was blocked by SP600125 pretreatment. Total JNK, p-JNK, 
total c-Jun and p-c-Jun were examined by western blot analysis (d) and NLRR2 mRNA 
expression was determined by RT-PCR (e). 
Figure 6. NLRR2 expression is induced by stress signals and contributes to drug 
resistance in neuroblastoma cells. (a) TGW, SK-N-BE and SMS-SAN cells were treated 
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with TM for the indicated time period. The expressions of NLRR2 mRNA were 
measured by quantitative real time PCR. TM induced the expression of NLRR2. (b) SK-
N-BE, SMS-SAN cells were treated with CDDP for the indicated time period. The 
expressions of NLRR2 mRNA were measured by quantitative real time PCR. NLRR2 
expression was induced by CDDP. (c d) SK-N-BE mock and NLRR2 bulk stable cells 
were treated with RA and TM. Cell survival was analyzed using a real-time cell imaging 
system. NLRR2 bulk stable cells showed significant resistance to RA (c) and TM-
mediated (d) cell growth inhibition.  
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Supplementary Information 
Supplemental figure 1. siNLRR2 (50 nM) and si-c-Jun (200 nM) reduced the expression 
of NLRR2 and c-Jun in SK-N-BE cells, respectively. SK-N-BE cells were transfected 
with siRNA according to the manufacturer’s protocol. Expression of NLRR2 and c-Jun 
was detected by real time PCR and RT-PCR, respectively 
Supplemental figure 2. Retinoic acid (RA) induced TGW cell differentiation in a dose 
dependent manner. TGW cells were treated with RA (0, 0.5, 1.0, 2.5, 2.5 or 5.0 µM) for 
24 hours and the percentage of differentiated cells was counted (left and right panel). 
Supplemental figure 3. RA induced NLRR2 and c-Jun expression in HeLa cells. HeLa 
cells were stimulated with RA for the indicated time period. NLRR2 levels were 
determined by quantitative RT-PCR. 
Supplemental figure 4. RA-mediated upregulation of NLRR2 was suppressed by JNK 
inhibition. TGW cells were stimulated with RA in the presence or absence of SP600125 
for 24 hours. NLRR2 levels were determined by quantitative RT-PCR. 
Supplemental figure 5. Exogenous expression of NLRR2 inhibited RA-induced 
differentiation of NB cells. SK-N-BE mock and NLRR2 bulk stable cells were treated 
with RA for 4 days. Cell images were taken from a real-time cell imaging system. The 
percentage of differentiated cells per field was counted (3 fields per well, 5 wells in each 
group). Data are presented as the mean ± SD. 
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Supplemental figure 6. c-Fos and ATF-2 expression was suppressed by RA in NB cells. 
NB cells were treated with RA (1.0 μM for TGW cells, 2.5 μM for SK-N-BE and SMS-
SAN cells) for the indicated time periods. c-Fos and ATF-2 expressions were determined 
by western blotting. 
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Figures 
Figure 1. NLRR2 is correlated with poor survival outcome in human NB and regulates 
tumor cell growth in vitro and in vivo. 
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Figure 2. NLRR2 knock down cells are susceptible to RA-mediated inhibition of cell 
survival and differentiation.  
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Figure 3. c-Jun is important for regulating NLRR2 expression induced by RA. 
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Figure 4. NLRR2 transcription is enhanced by RA through the recruitment of c-Jun onto 
the promoter of NLRR2 while JNK inhibition suppresses the promoter activity.  
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Figure 5. The JNK pathway is important for regulating NLRR2 expression. 
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Figure 6. NLRR2 expression is induced by stress signals and contributes to drug 
resistance in neuroblastoma cells. 
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Supplemental figure 1. siNLRR2 (50 nM) and si-c-Jun (200 nM) reduced the expression 
of NLRR2 and c-Jun in SK-N-BE cells, respectively. 
 
 
 
 
 
 
 
 
 
Supplemental figure S2. Retinoic acid (RA) induced TGW cell differentiation in a dose 
dependent manner. 
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Supplemental figure S3. RA induced NLRR2 and c-Jun expression in HeLa cells. 
 
 
 
 
                                           
 
 
 
 
 
 
 
Supplemental figure S4. RA-mediated upregulation of NLRR2 was suppressed by JNK 
inhibition. 
 
 
 
                                           
 
 
 
 
 
 
 
37 
 
Supplemental figure S5. Exogenous expression of NLRR2 inhibited RA-induced 
differentiation of NB cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental figure S6. c-Fos and ATF-2 expression was suppressed by RA in NB cells. 
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